Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
51 hedge funds and large institutions have $115M invested in Finch Therapeutics Group, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
16% more funds holding
Funds holding: 44 → 51 (+7)
8% more capital invested
Capital invested by funds: $107M → $115M (+$8.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$9.94M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.93M |
| 3 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
+$1.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$988K |
| 5 |
E
Ergoteles
New York
|
+$816K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$970K |
| 2 |
AI
Aperture Investors
New York
|
-$470K |
| 3 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$342K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$325K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$230K |
FNCH Hedge Fund Activity: Q4 2021 in Review
51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q4 2021, worth a combined $115M — up 7.7% from $107M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new FNCH positions and 3 closed out — a net gain of 7 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was MSD Partners, adding an estimated $9.94M. The largest seller was Baupost Group, cutting an estimated $970K.
- 51 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q4 2021, up from 44 in Q3 2021.
- Funds reported $115M of Finch Therapeutics Group, Inc. Common Stock stock for Q4 2021, up 7.7% quarter-over-quarter.
- 10 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q4 2021 and 3 closed out, a net change of +7 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q4 2021 was MSD Partners, an estimated $9.94M added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q4 2021 was Baupost Group, an estimated $970K sold.
Based on aggregated 13F filings for Q4 2021.